CNS Pharmaceuticals Commences Patient Enrollment in Potentially Pivotal Study of Berubicin
May 19, 2021 at 11:04 AM EDT
CNS Pharmaceuticals today announced open enrollment for its potentially pivotal study evaluating the efficacy and safety of Berubicin in the treatment of recurrent GBM.
